About-Evergreen Therapeutics, Inc.

About Evergreen

Focus on Unmet Clinical Needs and Achieve Medical Value

Evergreen Therapeutics is a Maryland-based innovative biopharmaceutical company established in 2019 with artificial intelligence (AI) as one of its core technologies. we have a cross-border integration team that brings together top talents in clinical medicine, computing science, chemistry, pharmacology, and FDA regulations in product registration, focusing on the discovery of innovative drugs in the field of ophthalmology, vascular and autoimmunity, as well as the efficient clinical development and commercialization on a global scale.

We always adhere to the principles of true clinical differentiation, high efficiency, and development to satisfy the needs of the major global markets. Evergreen uses the unique AI computing platform for the entire drug development life cycle from the synthesis and optimization of novel molecules, pharmacological and toxicological prediction to indication selection and optimization in clinical trial designs. Currently, the company’s pipeline consists of 10 programs, 5 of which have entered clinical development stages of Phase I-III in the United States. With more than 50 patent applications, covering major global pharmaceutical markets including the United States, Europe, China, and Japan.

In addition to developing in-house pipeline, we provide new drug development services to other pharmaceutical companies. Our regulatory and clinical consulting services cover various therapeutic areas apart from the three in-house therapeutic areas. Our strong pharmaceutical and international regulatory background enables us to provide services on precise AI-enabled clinical study design and fast application of FDA's expedited programs. Our goal is to improve the efficiency and success rate of drug development for the entire pharmaceutical industry.

10 Product Pipelines

50+ Patents Applications

5 Clinical Drug Candidates

Development History

2023

01-05:

Signed cooperation agreement with Baidu AI Cloud

02-17:

Awarded by MIT Technology Review China as "Digital Health Companies China 50"

05-06:

Awarded as VB100 “China Innovative Biotech Top 100” and “AI Biotech Value Top 5”

05-17:

2023：Dr. Tom Du recognized as a "2023 Science and Technology Entrepreneur" by 36Kr.

06-05:

Formed strategic partnership with CDMO leader BojiMed

12-15:

Awarded as “Influential Digital Life and Healthcare Enterprise 2023”

2022

02-04:

The new molecular drug EG-301 discovered by the Evergreen AI platform has been cleared by the US FDA for entry to phase II clinical trail

05-28:

Reached Strategic Cooperation with HwaGen Pharmaceutical

06-15:

Awarded as VB100 "Top 100 Innovative Biomedicine List" Enterprises

09-15:

Won the 2022 "EY Fudan Most Potential Enterprise" award, becoming one of only two pharmaceutical companies to receive this award

2021

03-15:

Raised RMB 100 million in Series A financing to develop highly demanded drugs

07-19:

Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer

08-11:

The U.S. Food and Drug Administration (FDA) has cleared the entry of EG-007 into a pivotal phase III clinical trial

2020

01-01:

Dr. Du Xin joined Evergreen Therapeutics Inc. as CEO

09-23:

EG-009 was officially approved by the FDA for phase I clinical trials

10-13:

EG-001 was officially approved by the FDA for phase I clinical trials

2019

08-26:

Evergreen Therapeutics Inc. was formally established

09-05:

Cooperate with McGill University in the research and development of respiratory drugs

2023

01-05:

Signed cooperation agreement with Baidu AI Cloud

02-17:

Awarded by MIT Technology Review China as "Digital Health Companies China 50"

05-06:

Awarded as VB100 “China Innovative Biotech Top 100” and “AI Biotech Value Top 5”

05-17:

2023：Dr. Tom Du recognized as a "2023 Science and Technology Entrepreneur" by 36Kr.

06-05:

Formed strategic partnership with CDMO leader BojiMed

12-15:

Awarded as “Influential Digital Life and Healthcare Enterprise 2023”

2022

02-04:

The new molecular drug EG-301 discovered by the Evergreen AI platform has been cleared by the US FDA for entry to phase II clinical trail

05-28:

Reached Strategic Cooperation with HwaGen Pharmaceutical

06-15:

Awarded as VB100 "Top 100 Innovative Biomedicine List" Enterprises

09-15:

Won the 2022 "EY Fudan Most Potential Enterprise" award, becoming one of only two pharmaceutical companies to receive this award

2021

03-15:

Raised RMB 100 million in Series A financing to develop highly demanded drugs

07-19:

Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer

08-11:

The U.S. Food and Drug Administration (FDA) has cleared the entry of EG-007 into a pivotal phase III clinical trial

2020

01-01:

Dr. Du Xin joined Evergreen Therapeutics Inc. as CEO

09-23:

EG-009 was officially approved by the FDA for phase I clinical trials

10-13:

EG-001 was officially approved by the FDA for phase I clinical trials

2019

08-26:

Evergreen Therapeutics Inc. was formally established

09-05:

Cooperate with McGill University in the research and development of respiratory drugs

Leadership

Tom Du, M.D., Ph.D.

Founder, Chairman

Tom Du, M.D., Ph.D.

He graduated from Tianjin Medical University and received his PhD from McGill University in Canada. He received two years of post-doctoral training at Harvard University in the United States, under professor Frank Austen, member of the National Academy of Sciences. Since 1994, he has served as a new drug reviewer for FDA for 7 years. After joining FDA in late 2000, he served as the Director of The Registration Division of United Healthcare Corporation in the United States and senior Director of Clinical and Registration Division of Hutchison Whampoa Pharmaceuticals in Hong Kong. Since then, he has served as Humphrey's chief pharmaceutical development consultant in Humphrey Medical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete more than 100 new drug development and application work. He is currently a visiting professor of Peking Union Medical College, president of FDA Society and president of the Association of Regulations and Agreements.

The Team Has Strong Independent Research And Development Capabilities

Executive Team
AI Research Team
Drug R&D Team
Business Team

David Du, Ph.D.

Co-founder, CEO

David Du, Ph.D.

He received his PhD in Biochemistry from the University of Florida in the US. He also did his postdoctoral research at the National College of Medicine. Former FDA reviewing officer, and senior executives of several pharmaceutical MNCs. Fully familiar with the FDA and global drug development process, including manufacturing, quality management, clinical design, drug product marketing application, and global post-marketing management of drug products. Dr. Du used to be a CMC reviewer of FDA, responsible for IND and BLA review of biologics. Thereafter, he worked at Aventis-Pasteur/Sanofi, Wyeth/Pfizer, Novartis, BMS, NPS and other multinational pharmaceutical companies. With more than 20 years of experience in the pharmaceutical industry, he has managed to obtain 4 BLAs from FDA, 2 biological approvals in the EU and Canada, as well as numerous IND clearances in the US, China, the EU, and other countries, involving various types of products such as large and small molecules, cells and genes, oncolytic viruses and drug device combinations. He also has experience in managing marketed drugs in more than 30 countries.

Charles Lee, M.D., Ph.D.

Co-founder, CMO

Charles Lee, M.D., Ph.D.

He graduated from Xi 'an Jiaotong University School of Medicine and received his Master's degree in hospital Administration and doctor of Public Health degree from the University of Alabama Birmingham, USA. He did three years of residency at the University of Chicago Medical Center and obtained the American Physician license and the American Clinical Pathology Specialist certification. He used to be a senior medical reviewer of THE US Food and Drug Administration (FDA), and was the first overseas Chinese to enter FDA's clinical review as a doctor. Dr. Charles Lee has extensive experience in phase I-IV global clinical trials in oncology, immunotherapy, anti-inflammatory, gastrointestinal diseases, and gynecological diseases. He has led hundreds of clinical trials and more than 30 new drug filings worldwide, developing overall solutions for global drug development, regulatory registration, clinical strategy and risk management.

Bill Wang, Ph.D.

Director of AI Bioinformatics

Bill Wang, Ph.D.

Graduated from Beijing Normal University, received his Ph.D. in Biology from Uppsala University, and postdoctoral fellow at Kanarinska Institutet, Sweden; He was a former Director of the Bioinformatics Centre at the University of Melbourne, and is a scientist with many years of experience in bioinformatics engineering and genomics research.

Xuhan Liu Ph.D

Associate Director of AI Algorithms

Xuhan Liu Ph.D

Graduated from the Academy of Science of Leiden University in the Netherlands, he obtained a Ph.D. in Computational Medicinal Chemistry, and worked at Beijing Oriental Yamei Gene Technology Co., Ltd. as a Bioinformatics Engineer. His main research direction is artificial intelligence design of new drug molecules, and he has in-depth research in the fields of data mining, algorithms, protein engineering, and molecular simulation.

Patrick McGrath, Ph.D

VP, Clinical Operation

Patrick McGrath, Ph.D

PhD at University of Missouri, rich experience in clinical design, operation, and regulations in multiple therapeutic areas, professional knowledge of prescription drugs regulations in the U. S., is responsible for implementing the company's clinical trials.

Shanshan Li, Ph.D.

Director of CMC

Shanshan Li, Ph.D.

Bachelor of Chemistry, Tsinghua University; Doctor of Pharmacy, Rutgers University, New Jersey, USA; With nearly 10 years of CMC working experience in the pharmaceutical industry, I am proficient in leading the whole industry chain process of topic selection and project approval, formula research and development, scale-up production, FDA application, commercial batch production and listing of products.

Kevin Wang

CBO

Kevin Wang

Graduated from the University of Miami with an MBA and a Master of Biostatistics. He has more than 15 years of experience in the pharmaceutical industry and more than 5 years of business development experience. He has worked in US-listed pharmaceutical companies and pharmaceutical consulting companies for many years, and has worked in AOB and Humphrey Pharmaceutical Consulting, serving as Deputy General Manager of Business Development and Assistant to the president. He is familiar with the daily operation of innovative pharmaceutical companies and has extensive experience in business cooperation, patent planning and technology transfer of pharmaceutical projects.

James Diao

Senior Director of Public Affairs

James Diao

Graduated from Newcastle University Business School; and received a MSc in Project Management from the University of Manchester; with PRINCE2 certified for project management by UK government. He started his healthcare career at Omnicom Health Group AP and served as Executive Assistant; he provided market consulting services for several MNCs including MSD, Pfizer and Novartis. Prior to joining Evergreen, he was the Vice President of Continental Capital and has abundant experience in the market research and investment field of the pharmaceutical industry.

Minghan Cui

Business Development Director

Minghan Cui

Master of Pharmaceutical Engineering, South China Agricultural University; Used to be the marketing manager of clinical Coordination Department of Hengrui Pharmaceutical. Pfizer China Cardiovascular Group SMICS; Researcher of Pharmaceutical Research Institute of Guangyao Baiyunshan Pharmaceutical General Factory.

Bertram Cai

BD Associate Director

Bertram Cai

Master of Biochemistry and Molecular Biology, Anhui University. Worked for Pfizer China cardiovascular and anti-inflammatory and analgesic unit as SMICS; SMICS for the full product of Bo Ruilin Group.

Scientific Advisory Committee

Florence Houn, M.D. Clinical Development Consultant of Anticancer and Other Drugs

Dr. Houn is a former outstanding leader of FDA, having served as the Office Director of CDER, CBER, and CDRH for 15 years. She also served as executive in MNCs, and is a former professor at Johns Hopkins University and an oncologist. Dr. Houn is currently a clinical development consultant of anticancer and other drugs in Evergreen.

James Martin, M.D.Clinical Development Consultant in Basic Science and Respiratory Diseases

Dr. Martin is a renowned respiratory specialist, former chief of internal medicine at McGill University, former director of the Respiratory Disease Institute, and a leading expert in asthma and COPD, especially in asthma pathophysiology research. Currently he serves as a consultant of Evergreen on basic science and clinical trials of respiratory diseases.

Paolo Baroldi, M.D., Ph.DClinical Development Consultant of Immunology

PhD in Clinical Pharmacology, Diploma from Harvard Business School Executive Education. An outstanding physician and clinical pharmacologist with more than 35 years of experience in pharmaceutical industry and drug development led the R&D of 25 new drugs including epirubicine, imatinib. Expertise in a wide variety of therapeutic areas.

Richard Moore, M.D. Clinical Development Consultant in Oncology

Dr. Moore is the Chair of Department of Gynecologic Oncology at the University of Rochester Medical Center. Former chair of the Department of Gynecologic Oncology at Brown University. He is an internationally recognized expert who uses biomarkers to detect ovarian cancer. Dr. Moore has a strong professional relationship with Evergreen and currently serves as the clinical development consultant in oncology.

Robert Malone, M.D. Clinical Development Consultant of COVID-19 Drugs

Dr. Malone is renowned infectious disease expert. He received M.D. degree in Northwestern University, was postdoctoral fellow at Harvard University. He has more than 20 years of experience in clinical development of new drugs and participated in the design and supervision of about 40 clinical trials from Phase I to Phase III. Currently he is serving as a consultant of Evergreen on novel Coronavirus treatment drug development.

James Handa, M.D. Clinical Development Consultant for Fundus Diseases

Director of the Department of Retinology at the Johns Hopkins University School of Medicine, Wilmer Institute of Ophthalmology; Doctor of Medicine from the University of Pennsylvania School of Medicine; Worked at Wells Eye Hospital in Philadelphia, Duke University Eye Center, and UCLA Children's Hospital; He has studied ophthalmic retinal, vitreous, and ophthalmic tumor diseases for many years, published hundreds of scientific research articles, and developed animal models of dry AMD.

Roy Vaz, Ph.D.Consultant for AI-assisted Drug Development

Head of Structural Biology, Computer-Aided Drug Design, and Chemoinformatics at Sanofi, US ; Dr. Vaz has extensive experience in AI drug discovery in the fields of rare diseases, immunology, and neuroscience, providing computer-aided drug design for projects in these areas.

About EvergreenABOUT EVERGREEN